Parabilis Medicines (NASDAQ:PBLS – Get Free Report) was upgraded by Wall Street Zen to a “hold” rating in a research report issued on Saturday.
Parabilis Medicines Stock Performance
PBLS opened at $25.85 on Friday. Parabilis Medicines has a twelve month low of $24.51 and a twelve month high of $34.47.
Insider Buying and Selling
In other Parabilis Medicines news, Director Alan Sebulsky purchased 9,065 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was purchased at an average cost of $26.49 per share, for a total transaction of $240,131.85. Following the acquisition, the director owned 30,000 shares in the company, valued at approximately $794,700. The trade was a 43.30% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 30,000 shares of company stock worth $723,528 over the last quarter.
See Also
- Five stocks we like better than Parabilis Medicines
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
